Posted by Peter on 3-13 7:09 pm
Tags: CDER, Center for Drug Evaluation and Research, communicate final inspection classifications, facility evaluation efforts, FDA, Food and Drug Administration, for-cause inspections, generic drugmakers, human drugs, implement the plan, Janet Woodcock, meet commitments, Melinda Plaisier, office of inspection, Office of Regulatory Affairs, operationalize the plan, ORA, reauthorized user fee agreements, specific operating models for pre- and post-approval inspections, streamline, surveillance inspections
Categories:
Drug Approval
General
Government
Market
Regulation
The Industry
